Introduction
Several genetically determined muscle disorders are caused by loss-of-function mutations and present at birth or in early childhood. Viral vectors delivered in utero offer a potential means of gene therapy for these disorders that primarily affect the striated muscle.
Adeno-associated viral (AAV) vectors provide efficient gene delivery to the striated muscle tissues. 1 Recently identified AAV serotypes have varied tissue tropism and transduction efficiency. Among the currently known serotypes, AAV8 shows superior potential to deliver transgenes to the muscle tissues. [2] [3] [4] [5] [6] [7] [8] [9] Using systemic delivery of AAV8 vectors, both reporter gene and therapeutic gene transfer studies in postnatal mice and hamsters showed efficient transduction of skeletal muscle and heart in neonates and adults. 6, 7 Similarly, Nakai et al. showed the ability of AAV8 vector to deliver a transgene to the skeletal muscle by systemic gene delivery in adult mice. 6 Other studies also showed that AAV8 vector effectively transduced nonhuman primate skeletal muscles. 5 In disease models, AAV8 vectors have shown potential for therapeutic benefit. In response to AAV8 vectormediated myostatin-inhibitor gene transfer to mdx mice, skeletal muscle mass increased. 4 AAV8 vector-mediated a-glucosidase gene transfer decreased glycogen storage in the skeletal muscle of a mouse model of Pompe disease. 3, 9 Furthermore, the AAV8 vector appeared to be less immunogenic 10 and showed more rapid uncoating post-internalization 11 compared with the AAV2 vector. In addition, the AAV8 vector also showed good potential to deliver transgenes in various animal models, such as mouse, rat, and nonhuman primates. 7, [12] [13] [14] The AAV8 vector also showed high-level transduction in various tissues, such as pancreatic cells, 15 neuronal cells, 16, 17 liver cells, 18 and smooth muscle cells. 17 Although AAV8 vectors have been extensively studied in various animal models and in different age groups, their transduction potential in utero remains unknown. Preclinical studies have shown that in utero gene delivery results in good expression of transgene extending into adulthood. Intramuscular injection of AAV1 19 and AAV2 20 vectors into fetal muscle showed good gene expression. However, systemic delivery of AAV1 vector in utero did not transduce limb muscle tissue to any significant degree. 19 This study, therefore, aims to determine the distribution of AAV8 vector particles to different tissues and levels of expression after in utero systemic delivery.
Results

Tissue biodistribution of lacZ expression after intraperitoneal administration of AAV8lacZ in utero
To determine the biodistribution and gene transfer efficiency of systemically delivered AAV8 in utero, 6.4 Â 10 11 vector genomes of AAV8 vector carrying a lacZ expression cassette driven by the human cytomegalovirus promoter (AAV8lacZ) were injected intraperitoneally per fetus on embryonic day 16 (E-16). At 9 weeks of age, the tissues were collected from injected pups, uninjected littermates, and mothers carrying the treated pups. To assess the results of gene delivery, all tissues were analyzed for the expression of b-gal by X-gal staining. By whole tissue staining, diaphragm, intercostal muscles, and abdominal muscles from the injected pups had the highest levels of b-gal expression (Figure 1 ). Moderate levels of expression were seen in hindlimb muscles, forelimb muscles, and heart. Minimal to undetectable levels of expression were observed in liver, lung, spleen, and kidney (data not shown).
Histological analysis of lacZ expression after intraperitoneal administration of AAV8lacZ in utero
Cryosections of diaphragm, quadriceps, gastrocnemius, tibialis anterior, forelimb muscle, and heart collected from injected pups at 9 weeks of age were stained for b-gal expression. Diaphragm exhibited b-gal expression in nearly all muscle fibers (Figure 2b) . A mosaic pattern of muscle fibers expressing b-gal was observed in forelimb, tibialis anterior, quadriceps, and gastrocnemius muscles (Figure 2) . A mosaic pattern of b-gal-expressing cells was observed in cross sections of heart with most transgene-expressing cells in proximity to the ventricles.
Quantification of b-gal protein expression in various tissues after intraperitoneal administration of AAV8lacZ in utero
To quantify the expression of protein, we performed the ONPG assay on protein extracts from multiple tissues. vector genomes of AAV8lacZ into E-16 pups of pregnant CD1 mice and stained for b-gal expression using X-gal. X-gal staining was observed in hindlimb (a), forelimb (b), heart (c), abdominal muscles (d), diaphragm (e), and intercostal muscles (f).
Systemic delivery of AAV8 in utero BM Koppanati et al Diaphragm and intercostal muscles exhibited high levels of expression of 7.73 ± 1.63 and 6.48 ± 0.94 units of b-gal per ng of protein, respectively (Figure 3a) . Quadriceps, tibialis anterior, gastrocnemius, forelimb muscle, and heart had moderate levels of expression of 2.2±0.46, 1.40 ± 0.28, 1.91 ± 0.41, 2.47 ± 0.43, and 1.39 ± 0.29 units of b-gal per ng of protein, respectively (Figure 3b) . Liver, lung, kidney, and spleen showed very low levels of expression of 0.51±0.21, 0.84±0.13, 0.22±0.11, and 0.14 ± 0.08 units of b-gal per ng of protein, respectively (Figure 3b ). There were no detectable levels of b-gal expression in diaphragm, intercostal muscles, quadriceps, gastrocnemius, tibialis anterior, forelimb, heart, liver, lung, spleen, and kidney tissues collected from the mothers that carried the treated mice in utero (data not shown).
Quantification of AAV vector genomes in various tissues after intraperitoneal administration of AAV8lacZ in utero
To determine the viral vector gene transfer efficiency, we quantified the number of viral particles in individual tissues by real-time PCR. The highest levels of viral vector particles were observed in the diaphragm and intercostal muscles. Diaphragm and intercostal muscles had 294.68±51.13 and 251.76±83.28 viral particles per 1000 nuclei, respectively (Figure 3a) . Quadriceps, tibialis anterior, gastrocnemius, forelimb muscle, and heart had 37.20±8.92, 15.52±3.03, 23.24±5.31, 62.72±19.40, and 13.80±4.13 viral particles per 1000 nuclei, respectively ( Figure 3b ). We also quantified the number of viral particles in non-muscle tissues. Liver, lung, kidney, and Figure 3b ). There were no detectable levels of vector genomes in diaphragm, intercostal muscles, quadriceps, gastrocnemius, tibialis anterior, forelimb, heart, liver, lung, spleen, and kidney tissues collected from the mothers that carried the treated mice in utero (data not shown).
Systemic administration of AAV8lacZ in utero shows preferential transduction of fast-twitch muscle fibers
To better understand the distribution of muscle fibers transduced by AAV8lacZ in utero, we correlated transduction efficiency with muscle fiber type. Myofibers can be classified as fast twitch or slow twitch based on the isoform of myosin heavy chain (MyHC) expressed. 21, 22 Earlier studies have shown that AAV2 preferentially transduced slow-twitch fibers and AAV6 transduced both fiber types in mice. [23] [24] [25] Similarly, another study showed that AAV9 preferentially transduced fast-twitch fibers in mice; 26 however, AAV9 did not show any fiber type transduction preference in dogs. 27 To determine whether the transduction by AAV8lacZ in utero correlated with fiber type, we performed double immunostaining with antibodies raised against b-gal and slow-twitch MyHC. Interestingly, we observed that the majority of b-gal-expressing muscle fibers did not express slow-twitch MyHC. However, rare slow-twitch fibers were transduced ( Figure 4 ).
Discussion
In this study, we systemically delivered AAV8 vector to E-16 mice in utero and analyzed the distribution of transgene expression and vector genomes in treated mice at 9 weeks of age. Although considerable AAV8 gene therapy studies have been done in adult and neonatal mice, the biodistribution of the AAV8 vector after in utero gene delivery has not been reported. Here, we provide the first report of the widespread gene expression in various muscles, including forelimb, diaphragm, intercostal, heart, tibialis anterior, quadriceps, and gastrocnemius muscles after AAV8 lacZ in utero injection. In addition to demonstrating lacZ gene expression by X-gal staining, we quantified gene expression by ONPG assay, and quantified the number of gene copies by real-time PCR. We observed a good correlation between the level of transgene protein expression and vector genome copy numbers in individual tissues. In particular, we observed highest levels of expression in diaphragm and intercostal muscles followed by other skeletal muscles. Interestingly, we noted minimal vector transduction in non-muscle tissues, such as the liver, lung, spleen, and kidney. Importantly, we observed no detectable levels of b-gal expression (by ONPG) or vector genomes (by TaqMan real-time PCR) in tissues collected from the mothers that carried the experimental mice in utero. Maternal tissues studied included diaphragm, intercostal muscles, quadriceps, gastrocnemius, tibialis anterior, forelimb, heart, liver, lung, spleen, and kidney.
Earlier studies have shown the potential of AAV8 vectors to deliver transgenes to muscle tissue of postnatal mice. [2] [3] [4] [5] [6] [7] [8] [9] With systemic administration, AAV8 vector exhibited better transduction in neonates than adults in mice suggesting systemic barriers to gene delivery that develop with maturation of adult tissues. 7 This suggested that in utero gene delivery of AAV8 would offer even more efficient gene delivery with potential benefit for the treatment of genetic diseases in particular. Consistent with the earlier postnatal AAV8 vector studies, we observed high gene transduction in the skeletal muscles with in utero AAV8 vector gene transfer. In this respect, we noted a widespread and mosaic pattern of gene expression throughout the various muscle groups both in the upper and lower limbs. Importantly, a high level of gene transduction was observed in the diaphragm and intercostal muscles when gene delivery of AAV8 vector was accomplished in utero.
Some parallels can be drawn between gene delivery in utero and neonatal mice by comparing our results with an earlier AAV8 systemic delivery study in neonatal mice published by Wang et al. 7 In this study, 1-day-old mouse pups treated with intraperitoneal administration of AAV8 showed high transduction efficiency in various muscle tissues for up to 2 months. The dose and period of analysis of the neonatal study were comparable to our 
in utero study. Similar to the neonatal study, we observed expression in various muscle tissues, heart, and diaphragm. Furthermore, similar to the neonatal study, our study also showed minimal to undetectable expression in non-muscle tissues, such as liver, lung, kidney, and spleen.
Earlier studies of viral vectors injected in utero have exhibited promising, but varying, abilities to deliver transgenes to different tissues. 19, 20, 28, 29 33 Although some of the earlier in utero studies using viral vectors, such as AAV1, 19 AAV2, 19 and AAV5, 31 showed minimal skeletal muscle expression, our study using AAV8 in utero systemic gene delivery showed significant levels of widespread gene delivery to the skeletal muscles, including forelimbs and hindlimbs. Furthermore, the high level of gene transduction in respiratory muscles was accomplished with a relatively low dose of AAV8 vector.
Different patterns of association of gene transduction to muscle fiber type have been observed for different AAV serotypes. Although studies have shown that AAV6 transduces both fast-and slow-twitch fibers in young adult mice (5-6-week-old C57BL/6) in extensor digitorum longus and soleus muscles 24 but with a trend toward preferential transduction of fast-twitch fibers treated in 3-day-old mdx hindlimb muscle, 23 it has also been shown that AAV2 preferentially transduces slow-twitch fibers in hindlimb muscle of both newborn and adult mice. 25 Moreover, studies with AAV9 showed that both fiber types were transduced in gastocnemius muscle of newborn dogs and that AAV9 transduction was independent of laminin receptor (LamR) expression, 27 a known receptor of AAV9. 34 In contrast, studies in soleus and tibialis anterior muscles of newborn and young adult (7-week old) C57BL/10 mice showed that AAV9 preferentially transduced fast-twitch fibers. 26 Hence, to further understand the transduction profile of AAV8 in utero, we studied the fiber type transduction in tibialis anterior muscle. We observed preferential transduction Systemic delivery of AAV8 in utero BM Koppanati et al of fast-twitch fibers. However, we also noted transduction of rare slow-twitch fibers. Further studies will be required to understand the reasons for fiber type preference in transduction that seems to depend on vector serotype and host factors, such as species and age. Studies have shown that many viral vectors injected systemically into adult mice preferentially transduce the liver. 2, 7 However, our in utero gene delivery data, consistent with other in utero studies, 19, 28, 29 showed minimal transduction of viral vectors into liver. It is interesting to note that even when delivered by the intrahepatic route, in utero injection of AAV2 provided minimal liver transduction (o1%) at days 21 and 70 post treatment in mice. 20 Similarly, intramniotoic injection of AAV2 to transduce rabbit fetuses showed no transduction into liver tissue. 29 These and other studies 19, 28 showed very low transduction of the liver by in utero gene transfer. This possibly is due to high cell turnover and unique properties in the fetal liver compared with the adult liver. [35] [36] [37] From the standpoint of safety this is significant, as liver transduction often leads to toxicity and has been an important limitation of the clinical viral vector gene transfer studies. 38 Furthermore, liver transduction is generally not desired as a component of muscle gene transfer strategies.
Studies have shown that intraperitoneal injections of vectors, such as AAV1 and AAV2, have varying abilities to transduce the murine heart in utero.
19,39 Lipshutz et al. 39 showed that although the gene expression of AAV2 in the peritoneum of CD1 mice continued to persist up to 18 months post in utero transuterine intraperitoneal injection, the expression in heart declined. Similarly, it has been shown that although the diaphragm showed high transgene expression for up to 4 weeks after intraperitoneal in utero treatment of AAV1, the heart showed minimal expression in C57BL/6 mice. 19 Hence, to understand the transduction ability of AAV8 vector in heart after in utero gene delivery, we performed X-gal staining and quantitative assessment of b-gal expression. We observed that although the transgene expression levels in heart did not reach as high as most limb muscles, we did observe b-gal-expressing cells in close proximity to the ventricles with levels approaching that of the limb muscle tissues.
Given that many muscular dystrophy patients require ventilatory assistance and many die because of respiratory failure, the high amount of AAV8 vector transduction observed in respiratory muscles offers the potential to provide functional benefit to these patients. In addition to disorders because of deficiencies of muscle membrane proteins such as Duchenne muscular dystrophy, AAV8 also has the potential as a gene delivery vector in other genetic muscle diseases in which patients die because of respiratory failure such as Pompe disease. 40 Patients suffering from infantile-onset Pompe disease start showing symptoms at a median age of 1.6 months and die at a median age of 6-8 months. 40 Thus, the significance of effective vector transduction into respiratory muscles prenatally could potentially help improve the clinical condition of these patients.
In this report we show the potential of systemic delivery of AAV8 vector in utero to achieve widespread muscle transduction with especially high levels in respiratory muscles. The findings suggest the therapeutic potential for delivering genes systemically to muscle cells of disease models by in utero gene delivery of AAV8 vectors.
Materials and methods
Production of AAV8lacZ vector
AAV8lacZ vector stocks were generated by the tripleplasmid transfection method. 41 Briefly, the three plasmids are the AAV-CMV-lacZ vector plasmid, the mini-adeno-helper plasmid, and the AAV8 packaging plasmid containing the AAV2 Rep gene and AAV8 Cap gene, which has an ATG to ACG start codon mutation to increase the vector yield.
42 AAV8lacZ viral particles were purified by double CsCl gradient centrifugation and dialyzed three times against phosphate-buffered saline (PBS) containing 5% sorbitol. The titer of vector genomes was determined by a standard DNA dot-blot assay. was also injected as a means to identify treated mice after birth. A total volume of 8-10 ml of AAV8lacZ solution/ fetus was injected using a 33-G needle (Hamilton, Reno, NV, USA) attached to a PB600 syringe dispenser (Hamilton, USA). A dose of 6.4 Â 10 11 vector genomes was injected per fetus. For this study, we injected 14 pups from 9 pregnant CD1 mothers to achieve 8 positive pups. A total of eight treated and eight untreated littermate pups were studied.
Mice and in utero AAV8lacZ vector administration
Between 2 and 5 days after injection, the naturally delivered pups were examined using a fluorescence microscope to identify those pups that were injected by the presence of the fluorescent marker. At 9 weeks after injection, different tissues from the mother, the injected pups, and uninjected littermates were analyzed for biodistribution of b-galactosidase (b-gal) expression and vector content.
Whole muscle staining
Tissues such as forelimb muscle, hindlimb muscle, heart, diaphragm, intercostal muscle, and abdominal muscles were isolated from mice, washed in 1 Â PBS for 5 min, and stained for b-gal expression. Whole muscle tissues were fixed with 0.5% glutaraldehyde and immersed in 5-bromo-4-chloro-3-indole-b-D-galactopyranoside (X-gal) staining solution (5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 1 mg ml -1 X-gal, and 1 mM MgCl 2 ) for 1-2 h at 37 1C. Stained tissues were imaged using a Fujipix 5400 camera.
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Cryosections
The tissues that were analyzed were tibialis anterior, quadriceps, gastrocnemius, forelimb muscle, abdominal muscle, intercostal muscle, diaphragm, heart, liver, lung, spleen, and kidney. Tissue samples were snap frozen in 2-methylbutane cooled with dry ice. Half of the sample was used for preparing cryosections using a cryostat (Leica CM 1800 cryostat, Bannockburn, IL, USA) and the other half was used to extract protein and DNA. The cryosections taken on glass slides were stained for b-gal expression. Sections were fixed with 0.5% glutaraldehyde, stained in X-gal staining solution (5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 1 mg ml -1 X-gal, and 1 mM MgCl 2 ) for 2-3 h at 37 1C, mounted, and viewed with a Zeiss Axiophot microscope. 
Ortho-nitro-phenyl galactopyranoside b-gal expression assay
To quantitate b-gal expression, the ortho-nitro-phenyl galactopyranoside (ONPG) assay was performed on extracted protein from tissue samples. 43 Briefly, snapfrozen tissue samples were treated with TEES buffer (25 mM Tris-HCl pH 8.0, 2.5 mM ethylenediaminetetraacetic acid pH 8.0, 2.5 mM ethyleneglycoltetraacetic acid pH 7.4, 5% sodium dodecyl sulfate) on ice. Samples were then centrifuged at 14 000 rpm for 30 min and protein extracts were collected and stored at À80 1C until analysis. Subsequently, the protein extracts were used for ONPG assay and bicinchoninic acid protein assay (Pierce, Rockford, IL, USA). For the ONPG assay, serial dilutions of the protein extract were incubated at 37 1C for 30 min in a 96-well plate with a buffer containing the enzyme substrate for the reaction. The optical density of the reaction was then read at wavelength 420 nm. The quantified samples were presented as units of b-gal activity per ng of protein.
Real-time PCR assay
Total DNA was isolated from the muscle tissue by ethanol precipitation (Wizard genomic DNA purification kit, Promega, Madison, WI, USA). Viral genomes were quantified in DNA from tissue samples using real-time PCR as described earlier. 43 Briefly, a 50-ml PCR volume contained 10 ml of DNA, 200 nM of each primer, 200 nM probe, and 25 ml of TaqMan Universal Master Mix (PE Applied Biosystem, Foster City, CA, USA) containing 8% glycerol, 1 Â TaqMan buffer A, 5 mM MgCl 2 , 400 mM dUTP, 200 mM dATP, dCTP, dGTP (each), AmpliTaq Gold (0.025 U ml -1 ), and AmpErase UNG (0.01 U ml -1 ). The vector genomes were calculated by amplifying lacZ and normalized to endogenous mouse apolipoprotein B (a single copy gene used as an internal control) used to calculate the amount of DNA (and, thus, the number of nuclei) in each sample. The primers and probes for the lacZ 44 and apolipoprotein B 45 genes have been described earlier. The amount of DNA for each sample was calculated from the number of nuclei in each sample using the approximation that a murine diploid nucleus contains 6 pg of DNA. All real-time PCR assays were performed in MicroAmp optical 96-well reaction plates (PE Applied Biosystem). Amplification conditions of 2 min at 50 1C and 10 min at 95 1C for the first cycle, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min, were used. The results were presented as copies of vector particles per 1000 nuclei.
